Breaking News

Colorcon Ventures Invests in i20 Therapeutics

Will work together to accelerate i2O’s research and development efforts.

By: Contract Pharma

Contract Pharma Staff

i2O Therapeutics, a biotech company developing a platform to enable oral delivery of traditionally injectable biological drugs, has received a strategic investment from Colorcon Ventures, the corporate venture fund of Colorcon Inc.   In addition to this investment, Colorcon will collaborate with i2O to accelerate i2O’s research and development efforts. i2O previously announced its seed round of financing led by Sanofi Ventures and JDRF T1D Fund in April 2020.    “We welcome Colorcon Ventures as ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters